Guardant Health Inc Dossier
Qualitative Analysis
Business overview
Guardant Health, Inc. is a leading precision oncology company focused on transforming patient care and guarding wellness through its advanced blood and tissue tests, real-world data, and AI analytics. Founded in 2012, the company has established a comprehensive portfolio of clinical offerings spanning all stages of cancer care. This includes early cancer screening (Shield), minimal residual disease (MRD) and recurrence monitoring (Guardant Reveal), and treatment selection for advanced-stage cancer patients (Guardant360 and GuardantINFINITY). Guardant Health operates primarily in the United States but has been actively expanding its commercial footprint and clinical partnerships internationally.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A nationwide commercial collaboration with Quest Diagnostics to co-promote and perform EMR integration for the Shield colorectal cancer screening test.
Expected impact: Fast-tracks EMR connectivity to more than 650,000 healthcare providers, dramatically expanding Shield's market reach and clinical adoption.
Comprehensive direct-to-consumer and healthcare provider marketing campaigns, including a high-profile partnership with actor Patrick Dempsey, to raise awareness of the Shield colon cancer blood test.
Expected impact: Drives patient-initiated requests and physician familiarity, supporting the raised 2026 screening volume target of 230,000 to 245,000 tests.
Implementation of near-term greenhouse gas emissions reduction targets approved by the Science Based Targets initiative (SBTi) in December 2025.
Expected impact: Aligns corporate operations with science-based decarbonization pathways, reducing Scope 1 and Scope 2 emissions (measured at 1,666 and 2,325 mtCO2e respectively in 2025) and establishing a framework for Scope 3 value chain engagement.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire MetaSight's next-generation liquid biopsy technology, which utilizes mass spectrometry to analyze metabolites and lipids in blood samples. The technology is highly complementary to Guardant's Smart Platform and is expected to enhance its Shield colorectal cancer screening test.
Financial impact: The transaction involved $59 million in upfront cash and up to $90 million in potential regulatory and commercial milestone payments.